MedTrace Logo

Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients

NCT04524663 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2022-06-10

Study results available
· View outcomes & findings →

Summary

This study will evaluate the efficacy of oral Foipan® (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with mild-moderate COVID-19 disease.

Patients will attend 4 study visits over a period of up to 28 days.

Conditions

  • Covid19

Interventions

DRUG

Camostat Mesilate

Camostat Mesilate administered as oral tablets

DRUG

Placebo

Placebo to match camostat mesilate

OTHER

Standard of Care Treatment

Standard of Care Treatment for COVID-19 Infection

Sponsors & Collaborators

Principal Investigators

  • Julie Parsonnet, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-19
Primary Completion
2021-05-15
Completion
2021-05-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04524663 on ClinicalTrials.gov